• 1
    Sternberg CN, de Mulder P, Schornagel JH, et al; EORTC Genito-Urinary Cancer Group. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006;42:5054.
  • 2
    von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:30683077.
  • 3
    Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012;30:11071113.
  • 4
    Sonpavde G, Galsky MD, Vogelzang NJ. First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients? J Clin Oncol. 2010;28:e441e442.
  • 5
    Krajewski KM, Fougeray R, Bellmunt J, et al. Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. Eur J Cancer. 2012;48:14951502.
  • 6
    Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol. 2003;21:14041411.
  • 7
    Galsky MD, Hendricks R, Svatek R, et al. Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: A report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. Cancer. 2013; doi:10.1002/cncr.27973.
  • 8
    Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207214.
  • 9
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205216.
  • 10
    Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:31733181.
  • 11
    Galsky MD, Krege S, Lin CC, et al. Prognostic model for overall survival in patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy [Abstract]. Proc Am Soc Clin Oncol. 2012; abstract 4524.
  • 12
    Fleischer F, Gaschler-Markefski B, Bluhmki E. A statistical model for the dependence between progression-free survival and overall survival. Stat Med. 2009;28:26692686.
  • 13
    Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10:10661073.
  • 14
    Francart J, Legrand C, Sylvester R, Van Glabbeke M, van Meerbeeck JP, Robert A. Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma–The EORTC Lung Cancer Group. J Clin Oncol. 2006;24:30073012.
  • 15
    Mandrekar SJ, Qi Y, Hillman SL, et al. Endpoints in phase II trials for advanced non-small cell lung cancer. J Thorac Oncol. 2010;5:39.
  • 16
    Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol. 2010;12:274282.
  • 17
    Markman M. Use of progression-free survival as a valid endpoint in phase II cancer clinical trials. Curr Oncol Rep. 2007;9:159160.
  • 18
    Sleijfer S, Wagner AJ. The challenge of choosing appropriate end points in single-arm phase II studies of rare diseases. J Clin Oncol. 2012;30:896898.
  • 19
    Sharma MR, Stadler WM, Ratain MJ. Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst. 2011;103:10931100.
  • 20
    Choi JH, Ahn MJ, Rhim HC, et al. Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma. Cancer Res Treat. 2005;37:290293.
  • 21
    Nishino M, Jackman DM, Hatabu H, et al. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 2010;195:W221W228.
  • 22
    Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989;8:431440.
  • 23
    Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009;101:16421649.
  • 24
    Hahn NM, Stadler WM, Zon RT, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol. 2011;29:15251530.
  • 25
    Galsky MD, Hellerstedt BA, O'Rourke MA, et al. Phase II study of gemcitabine, cisplatin, and sunitinib in patients with advanced urothelial carcinoma. J Clin Oncol. 2012;30(suppl 5): abstract 282.
  • 26
    Ecke TH, Bartel P, Koch S, Ruttloff J, Theissig F. Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Oncol Rep. 2006;16:13811388.
  • 27
    Krege S, Rexer H, vom Dorp F, Albers P, De Geeter P, Klotz T. Gemcitabine and cisplatin with or without sorafenib in urothelial carcinoma (AUO-AB 31/05) [Abstract]. J Clin Oncol. 2010;28(15 suppl): abstract 4574.
  • 28
    Lin CC, Hsu CH, Huang CY, et al. Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity. Cancer. 2006;106:12691275.
  • 29
    Lin CC, Hsu CH, Huang CY, Cheng AL, Vogelzang NJ, Pu YS. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma. J Urol. 2007;177:8489.
  • 30
    Bamias A, Karadimou A, Lampaki S, et al. Prospective, randomized phase III study comparing two intensified regimens (methotrexate/vinblastine/doxorubicin hydrochloride/cisplatin [MVAC] versus gemcitabine/cisplatin) in patients with inoperable or recurrent urothelial cancer. J Clin Oncol. 2011;29(suppl): abstract 4510.
  • 31
    Bamias A, Aravantinos G, Deliveliotis C, et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004;22:220228.